What Lies Ahead for Biotech ETFs in 2016?

It has been a highly eventful year for the biotech sector thanks to mergers and acquisitions (M&A), deals galore, pricing controversy, stretched valuations and the usual pipeline updates. The NASDAQ Biotechnology index is up 7.7% YTD.